|1.||Supuran, Claudiu T: 17 articles (09/2015 - 03/2003)|
|2.||Swenson, Erik R: 13 articles (12/2015 - 01/2004)|
|3.||Ogawa, Akira: 10 articles (12/2015 - 07/2002)|
|4.||Ogasawara, Kuniaki: 10 articles (12/2015 - 07/2002)|
|5.||Kobayashi, Masakazu: 8 articles (12/2015 - 06/2003)|
|6.||Wall, Michael: 8 articles (10/2015 - 03/2002)|
|7.||Bloch, Konrad E: 8 articles (06/2015 - 01/2011)|
|8.||Basnyat, Buddha: 8 articles (01/2014 - 01/2003)|
|9.||Ulrich, Silvia: 7 articles (06/2015 - 01/2012)|
|10.||Terasaki, Kazunori: 6 articles (12/2015 - 09/2002)|
|1.||Altitude Sickness (Mountain Sickness)
01/01/2008 - "The efficacy of acetazolamide against acute mountain sickness, however, was significant with a 21.9% incidence in the placebo group compared to 10.2 % in the acetazolamide group (p < 0.01). "
10/01/1992 - "Evidence that Acetazolamide is beneficial for pulmonary oedema or cerebral oedema is scanty because of the lower frequency of these severe forms of mountain sickness. "
01/01/2004 - "The study objective was to determine whether acetazolamide is effective in prophylaxis of acute mountain sickness (AMS) at moderate altitude in ambulatory travelers not undergoing vigorous exercise. "
09/01/2012 - "Acetazolamide has been reported to be effective in the prevention of acute mountain sickness (AMS). "
01/01/2012 - "Acetazolamide at doses of 250 mg, 500 mg, and 750 mg were all effective in preventing acute mountain sickness above 3000 m, with a combined odds ratio of 0.36 (95% confidence interval 0.28 to 0.46). "
|2.||Pseudotumor Cerebri (Idiopathic Intracranial Hypertension)
02/01/2011 - "In the future, results from the ongoing multicenter, double-blind, placebo-controlled Idiopathic Intracranial Hypertension Treatment Trial (IIHTT) will provide important data regarding the efficacy of acetazolamide and the utility of diet and exercise."
05/01/1999 - "We report a study of 5 patients with benign intracranial hypertension, and severe visual loss (visual field loss and visual acuity reduced to 1/10 or less) not improved by medical therapy (acetazolamide). "
06/01/1997 - "The objective of the study was to determine the efficacy of optic nerve sheath fenestration (ONSF) in eyes with progressive visual or field loss in pseudotumor cerebri in spite of medical therapy with oral Diamox. "
01/01/2016 - "Investigators of the Idiopathic Intracranial Hypertension Treatment Trial (IIHTT) reported beneficial effects of acetazolamide in patients with mild visual loss. "
04/23/2014 - "Effect of acetazolamide on visual function in patients with idiopathic intracranial hypertension and mild visual loss: the idiopathic intracranial hypertension treatment trial."
08/01/2011 - "P-8 treatment improved the endurance of mice in the condition of hypoxia and worked better than Acetazolamide. "
12/15/2015 - "The net effect was improved cerebral tissue PtiO2 during acute hypoxia [11.4 (2.7) (hypoxia) to 16.5 (3.0) mmHg (hypoxia + acetazolamide), P < 0.05]. "
05/01/2011 - "Compared with placebo, acetazolamide reduced middle cerebral artery blood flow velocity (11%) and improved dynamic cerebral autoregulation after 9 h of hypoxia, but these effects appeared independent of AMS. "
11/01/2008 - "While the pre-treatment with intermittent hypoxia prolonged the constant SaO(2) periods, the intake of acetazolamide eliminated this respiratory periodicity. "
12/15/2015 - "In this study, we investigate whether low-dose oral acetazolamide (250 mg) reduces this elevated CMRO2 and in turn might improve cerebral tissue oxygenation (PtiO2 ) during acute hypoxia. "
01/01/2014 - "Significant macular edema in a patient with cone dystrophy and improvement with acetazolamide treatment."
03/01/1992 - "Acetazolamide has been shown to be beneficial in the treatment of macular edema. "
01/01/2001 - "Is acetazolamide effective in the treatment of diabetic macular edema? "
01/01/2013 - "The only intervention with sufficiently robust randomized controlled trials for a meta-analysis was acetazolamide, which was shown to be ineffective in improving vision in eyes with uveitic macular edema, and is clinically now rarely used. "
03/01/1993 - "The results show that acetazolamide is a basically effective agent against cystoid macular edema and that a therapeutical trial is justified based on the treatment criteria of this study. "
08/01/2014 - "In this study, we tested the hypothesis that acetazolamide also may induce headache and dilatation of cranial arteries. "
08/01/2014 - "In conclusion, acetazolamide caused immediate and delayed headache as well as dilatation of intracranial arteries in healthy volunteers. "
08/01/2014 - "The area under the curve for headache was increased after acetazolamide compared to placebo in the delayed phase (2-12 h) (P=.005). "
08/01/2014 - "Eleven participants reported headache in the delayed phase after acetazolamide, compared with 4 after placebo (P=.016). "
08/01/2014 - "Acetazolamide provoked immediate headache in 9 participants compared to 3 participants after placebo (P=.031). "
|1.||Carbonic Anhydrases (Carbonic Anhydrase)
|7.||Anticonvulsants (Antiepileptic Drugs)
|3.||Drug Therapy (Chemotherapy)